background
barrier
influenza
vaccin
mispercept
inactiv
vaccin
caus
influenza
previou
studi
investig
risk
acut
respiratori
ill
ari
influenza
vaccin
conflict
result
assess
whether
increas
rate
laboratoryconfirm
ari
postinfluenza
vaccin
period
method
conduct
cohort
subanalysi
children
adult
mosaic
commun
surveil
studi
influenza
vaccin
confirm
citi
hospit
registri
case
ari
ascertain
twiceweekli
text
messag
household
identifi
member
ari
symptom
nasal
swab
obtain
ill
particip
analyz
respiratori
pathogen
use
multiplex
pcr
primari
outcom
measur
hazard
ratio
laboratoryconfirm
ari
individu
postvaccin
compar
time
period
three
influenza
season
result
particip
children
adult
studi
season
approxim
half
receiv
influenza
vaccin
one
third
experienc
ari
hazard
influenza
individu
postvaccin
period
similar
unvaccin
individu
period
hr
ci
hazard
noninfluenza
respiratori
pathogen
higher
period
hr
ci
stratifi
age
hazard
remain
higher
children
hr
ci
adult
hr
ci
conclus
among
children
increas
hazard
ari
caus
noninfluenza
respiratori
pathogen
postinfluenza
vaccin
compar
unvaccin
children
period
potenti
mechan
associ
warrant
investig
futur
research
could
investig
whether
medic
decisionmak
surround
influenza
vaccin
may
improv
acknowledg
patient
experi
counsel
regard
differ
type
ari
correct
mispercept
ari
occur
vaccin
caus
influenza
influenza
vaccin
recommend
individu
month
older
contraind
howev
accept
influenza
vaccin
mani
barrier
includ
low
perceiv
vaccin
efficaci
low
perceiv
suscept
influenza
infect
lack
understand
potenti
sever
ill
influenza
inconveni
fear
advers
effect
parent
well
adult
patient
express
concern
acut
respiratori
ill
ari
occur
influenza
http
elsevi
ltd
right
reserv
abbrevi
ari
acut
respiratori
ill
mosaic
mobil
surveil
acut
respiratori
infect
influenzalik
ill
commun
nyp
newyorkpresbyterian
cir
citywid
immun
registri
vaccin
nation
survey
adult
held
belief
flu
vaccin
give
flu
plausibl
explan
patientperceiv
ill
immedi
follow
vaccin
includ
fever
side
effect
induc
inflammatori
mediat
influenza
infect
prior
vaccineinduc
immun
coincident
infect
respiratori
pathogen
addit
immunolog
interfer
relat
vaccin
may
modifi
risk
ari
potenti
differ
way
exampl
lack
viral
interfer
hypothes
increas
risk
ari
influenza
vaccin
temporari
nonspecif
immun
hypothes
decreas
risk
ari
influenza
vaccin
previou
studi
investig
risk
ari
influenza
vaccin
conflict
result
may
reflect
variat
studi
design
exampl
studi
includ
studi
popul
recruit
case
medic
attend
ill
may
reliabl
estim
popul
incid
ari
use
cohort
studi
design
compar
vaccin
unvaccin
individu
may
better
also
prone
bia
group
wellmatch
group
andor
unmeasur
confound
exist
addit
previou
investig
ari
risk
vaccin
lack
biolog
plausibl
tempor
relationship
vaccin
may
accur
estim
risk
ari
attribut
vaccin
goal
studi
assess
risk
ari
caus
laboratoryconfirm
influenza
laboratoryconfirm
noninfluenza
respiratori
pathogen
ari
symptom
without
pathogen
detect
suggest
noninfecti
etiolog
inflammatori
respons
postvaccin
risk
period
compar
period
influenza
season
hypothes
would
increas
risk
influenza
noninfluenza
respiratori
pathogen
symptom
without
pathogen
detect
postinfluenza
vaccin
risk
period
understand
risk
ill
postvaccin
period
may
use
develop
target
anticipatori
guidanc
parent
adult
patient
consid
influenza
vaccin
cohort
studi
part
communitybas
studi
mobil
surveil
acut
respiratori
infect
influenzalik
ill
commun
mosaic
follow
household
year
ari
surveil
recruit
elig
consent
procedur
mosaic
previous
describ
particip
primarili
immigr
latino
commun
northern
manhattan
new
york
citi
columbia
univers
medic
center
institut
review
board
approv
overal
studi
subanalysi
observ
period
subanalysi
consist
three
influenza
season
septemb
june
septemb
may
septemb
may
season
start
date
septemb
concurr
typic
avail
influenza
vaccin
end
date
season
vari
captur
case
laboratoryconfirm
influenza
cohort
subanalysi
children
month
year
age
elig
vaccin
record
newyorkpresbyterian
nyp
immun
registri
andor
new
york
citywid
immun
registri
cir
children
receiv
two
dose
influenza
vaccin
exclud
analysi
season
receiv
two
dose
due
potenti
challeng
interpret
event
occur
partial
vaccin
window
vaccin
citywid
registri
adult
vaccin
adult
year
age
elig
patient
nyp
academ
health
care
deliveri
system
includ
ambulatori
care
network
provid
primari
care
new
york
citi
underserv
commun
primari
care
visit
hospit
octob
end
studi
season
interest
elig
criteria
appli
order
ensur
confid
collect
influenza
vaccin
inform
appli
individu
studi
season
individu
includ
durat
activ
particip
studi
enrol
household
report
interview
member
studi
team
obtain
household
individu
demograph
characterist
includ
household
member
age
gender
health
statu
histori
chronic
respiratori
condit
household
size
number
schoolag
children
per
household
influenza
vaccin
data
individu
collect
nyp
vaccin
registri
captur
vaccin
administ
patient
age
nypaffili
commun
clinic
hospit
emerg
depart
new
york
cir
includ
vaccin
administ
patient
yearsold
new
york
citi
previous
describ
ari
case
ascertain
mosaic
studi
occur
twiceweekli
research
teamgener
text
messag
ask
household
report
anyon
household
ari
symptom
reportergener
text
messag
household
ill
could
also
sent
time
research
team
review
ari
criteria
household
report
phone
includ
follow
particip
year
old
rhinorrhea
nasal
congest
sore
throat
cough
fever
feverish
muscl
bodi
ach
particip
year
ari
defin
rhinorrhea
nasal
congest
alon
ari
case
ascertain
member
research
team
made
home
visit
within
h
symptom
onset
obtain
midturbin
nasal
swab
sampl
process
research
laboratori
via
multiplex
rtpcr
use
fdaapprov
filmarray
respiratori
panel
biofir
diagnost
inc
risk
period
examin
base
knowledg
postvaccin
reactogen
event
time
vaccin
effect
priori
hypothes
period
base
patient
experi
risk
period
chosen
assess
associ
vaccin
inflammatorymedi
reactogen
event
typic
occur
within
h
follow
vaccin
outcom
defin
ari
symptom
without
detect
pathogen
occur
day
vaccin
two
day
vaccin
risk
period
chosen
assess
associ
vaccin
event
relat
potenti
viral
interfer
temporari
nonspecif
immun
time
influenzaspecif
immun
develop
outcom
defin
ari
symptom
laboratoryconfirm
influenza
noninfluenza
respiratori
pathogen
occur
day
vaccin
day
vaccin
multivari
cox
proport
hazard
regress
model
use
estim
rel
hazard
ari
associ
three
vaccin
exposur
status
unvaccin
start
day
one
studi
season
day
enrol
day
vaccin
entir
studi
season
unvaccin
individu
postvaccin
describ
vaccin
start
postvaccin
risk
period
timevari
variabl
use
three
vaccin
status
multipl
ari
report
subject
cours
studi
period
repeat
event
subject
may
correl
frailti
model
use
frailti
model
includ
random
variabl
cox
model
order
adjust
potenti
unmeasur
confound
model
adjust
season
use
timevari
covari
autumn
septembernovemb
winter
decemberfebruari
spring
marchmay
june
three
timeindepend
covari
age
categor
year
gender
prior
diagnosi
chronic
respiratori
condit
collect
report
asthma
chronic
obstruct
pulmonari
diseas
andor
chronic
inhal
use
level
signific
set
sa
version
statist
softwar
sa
institut
inc
use
data
analysi
separ
model
conduct
three
primari
outcom
ari
base
nasal
swab
result
influenza
noninfluenza
respiratori
pathogen
ari
symptom
without
pathogen
detect
within
relev
postvaccin
risk
period
ie
influenza
noninfluenza
pathogen
risk
period
ari
symptom
without
detect
pathogen
risk
period
fig
analys
complet
influenza
season
separ
evalu
interseason
variabl
three
season
combin
assess
trend
increas
power
detect
differ
rate
ari
three
time
interv
posthoc
analys
complet
three
season
combin
better
understand
signific
find
includ
stratif
age
ie
children
age
year
versu
adult
age
year
sensit
analysi
includ
vaccin
individu
stratifi
age
sensit
analysi
exclud
individu
receiv
live
attenu
influenza
vaccin
sensit
analysi
exclud
two
day
follow
vaccin
risk
period
total
particip
children
adult
elig
inclus
studi
fig
subject
primarili
children
year
old
femal
approxim
chronic
respiratori
condit
tabl
approxim
half
vaccin
influenza
studi
season
tabl
vaccin
autumn
fig
vaccin
unvaccin
individu
differ
household
size
number
schoolag
children
per
household
gender
chronic
respiratori
condit
also
differ
time
sampl
symptom
onset
rate
vaccin
higher
among
youngest
rang
across
three
studi
season
oldest
particip
compar
year
among
vaccin
individu
receiv
live
attenu
influenza
vaccin
three
studi
season
respect
approxim
one
third
particip
experienc
least
one
ari
studi
season
howev
vaccin
particip
experienc
ari
postvaccin
risk
period
frequenc
ari
exposur
statu
shown
tabl
frequenc
distribut
date
onset
ari
date
vaccin
shown
fig
preval
type
influenza
influenza
b
follow
influenza
influenza
preval
type
influenza
influenza
follow
influenza
b
preval
type
influenza
influenza
b
follow
influenza
influenza
distribut
similar
among
unvaccin
vaccin
period
throughout
studi
season
preval
noninfluenza
ari
pathogen
detect
rhinovirusenteroviru
respiratori
syncyti
viru
coronavirus
distribut
similar
among
vaccin
unvaccin
period
hazard
laboratoryconfirm
influenza
individu
postvaccin
similar
unvaccin
individu
period
time
observ
studi
season
three
season
combin
tabl
hazard
ari
caus
noninfluenza
respiratori
pathogen
higher
individu
postvaccin
compar
unvaccin
individu
period
time
observ
two
three
studi
season
three
season
combin
hazard
ari
caus
noninfluenza
respiratori
pathogen
vaccin
individu
day
also
higher
unvaccin
individu
period
three
studi
season
hazard
ari
caus
noninfluenza
respiratori
pathogen
individu
postvaccin
similar
vaccin
individu
day
studi
season
three
season
combin
tabl
hazard
ari
symptom
without
detect
pathogen
similar
individu
postvaccin
risk
period
compar
unvaccin
individu
period
time
observ
studi
season
three
season
combin
hazard
ari
symptom
without
detect
pathogen
vaccin
individu
day
higher
unvaccin
individu
period
one
studi
season
three
season
combin
tabl
stratif
age
children
year
hazard
ari
caus
noninfluenza
respiratori
pathogen
remain
higher
children
postvaccin
risk
period
compar
unvaccin
children
period
ahr
ci
three
season
combin
hazard
also
higher
vaccin
children
compar
unvaccin
children
period
ahr
ci
three
season
combin
howev
adult
year
hazard
adult
postvaccin
risk
period
similar
unvaccin
adult
ahr
ci
three
season
combin
hazard
also
similar
vaccin
adult
compar
unvaccin
adult
period
ahr
ci
three
season
combin
sensit
analysi
perform
includ
children
ultim
receiv
influenza
vaccin
also
reveal
increas
hazard
ari
caus
noninfluenza
respiratori
pathogen
postvaccin
risk
period
compar
children
yet
vaccin
period
ahr
ci
three
season
combin
hazard
also
higher
vaccin
children
compar
yet
vaccin
children
period
ahr
ci
three
season
combin
among
adult
receiv
influenza
vaccin
signific
differ
hazard
ari
caus
noninfluenza
respiratori
pathogen
sensit
analysi
perform
exclud
individu
receiv
intranas
live
attenu
influenza
vaccin
hazard
ratio
estim
similar
analysi
includ
individu
episod
influenza
ari
associ
live
attenu
influenza
vaccin
exclud
two
day
follow
vaccin
risk
period
signific
differ
hazard
ari
caus
influenza
noninfluenza
respiratori
pathogen
potenti
associ
particip
characterist
season
ari
outcom
also
evalu
tabl
children
year
children
year
higher
hazard
noninfluenza
respiratori
pathogen
throughout
studi
season
compar
adult
year
old
chronic
respiratori
condit
higher
hazard
noninfluenza
pathogen
higher
hazard
ari
symptom
without
detect
pathogen
compar
without
chronic
respiratori
condit
winter
spring
associ
higher
hazard
influenza
compar
autumn
hazard
noninfluenza
pathogen
similar
among
season
hazard
symptom
without
detect
pathogen
higher
spring
compar
autumn
winter
cohort
studi
assess
risk
ari
postvaccin
risk
period
three
influenza
season
hazard
ari
caus
influenza
higher
individu
immedi
postvaccin
period
compar
individu
unvaccin
find
consist
implaus
acquir
influenza
inactiv
vaccin
similarli
consist
random
control
trial
ari
symptom
without
detect
pathogen
higher
individu
immedi
day
follow
vaccin
compar
individu
unvaccin
unexpectedli
among
children
year
adult
higher
hazard
ari
caus
non
influenza
pathogen
postvaccin
vaccin
day
compar
unvaccin
children
time
period
despit
higher
hazard
absolut
number
vaccin
individu
experienc
ari
postvaccin
risk
period
low
potenti
explan
postul
includ
bia
report
among
vaccin
individu
nonspecif
decreas
immun
respiratori
pathogen
among
vaccin
individu
latter
hypothesi
biolog
plausibl
valid
futur
studi
patient
experi
increas
respiratori
ill
influenza
vaccin
may
support
find
increas
rate
laboratoryconfirm
noninfluenza
respiratori
infect
day
follow
vaccin
howev
result
current
studi
interpret
reason
chang
recommend
univers
vaccin
prevent
influenza
potenti
sever
ill
complic
pneumonia
bacteri
infect
hospit
death
influenza
vaccin
demonstr
reduct
morbid
mortal
across
age
group
baselin
health
status
addit
other
also
suggest
interfer
occur
respiratori
virus
may
offer
protect
includ
influenza
infect
exampl
epidemiolog
studi
shown
peak
incid
one
major
viru
occur
major
virus
absent
epidem
high
circul
rhinoviru
associ
reduc
likelihood
franc
sweden
prior
studi
shown
conflict
result
postinfluenza
vaccin
risk
ari
similar
find
two
studi
found
increas
risk
laboratoryconfirm
noninfluenza
infect
vaccin
children
compar
unvaccin
children
month
follow
vaccin
howev
two
larg
vaccin
safeti
studi
research
find
increas
risk
medic
attend
ill
two
week
follow
vaccin
compar
control
period
vaccin
limit
period
evalu
studi
outcom
medic
attend
ill
may
captur
true
incid
ari
postvaccin
studi
conduct
singl
influenza
season
may
limit
generaliz
heterogen
among
circul
respiratori
virus
influenza
vaccineviru
antigen
match
differ
influenza
season
studi
attempt
overcom
limit
conduct
three
consecut
influenza
season
includ
nonmed
attend
event
examin
extend
postvaccin
period
studi
design
also
minim
recal
bia
ari
outcom
collect
yearround
surveil
use
textmessag
athom
nasal
swab
collect
independ
exposur
influenza
vaccin
support
studi
design
found
expect
result
associ
particip
characterist
season
laboratori
confirm
ari
exampl
children
greater
hazard
adult
noninfluenza
ari
throughout
studi
season
associ
chronic
respiratori
condit
spring
ari
without
detect
pathogen
may
suggest
season
allergi
observ
influenza
vaccin
significantli
reduc
overal
hazard
influenza
popul
though
number
influenza
case
small
predomin
influenza
type
subtyp
detect
among
vaccin
individu
season
consist
found
lower
vaccin
effect
estim
nation
studi
exampl
vaccin
low
effect
predomin
influenza
effect
influenza
b
trival
vaccin
includ
influenza
bvictoria
saw
vaccin
individu
popul
predominantli
affect
influenza
b
studi
limit
includ
observ
design
limit
causal
infer
influenza
vaccin
ari
adjust
import
covari
analyt
model
howev
potenti
unmeasur
confound
studi
popul
predominantli
uniform
characterist
ethnic
multigener
household
size
urban
neighborhood
low
socioeconom
statu
adjust
variabl
may
affect
rate
ari
limit
extern
valid
inclus
criteria
design
minim
misclassif
vaccin
statu
citi
registri
adult
immun
possibl
adult
includ
studi
miss
vaccin
data
vaccin
outsid
hospit
system
howev
sensit
analysi
includ
vaccin
adult
find
differ
rel
hazard
ari
compar
estim
includ
adult
statist
model
adjust
coadministr
vaccin
may
affect
risk
system
side
effect
vaccin
vaccin
individu
like
get
influenza
influenza
vaccin
howev
patient
experi
ill
vaccin
may
valid
result
suggest
increas
risk
ari
caus
noninfluenza
respiratori
pathogen
follow
influenza
vaccin
among
children
year
mechan
rel
increas
may
occur
warrant
investig
futur
research
could
investig
whether
medic
decisionmak
surround
influenza
vaccin
may
improv
acknowledg
patient
experi
counsel
regard
differ
type
respiratori
virus
correct
mispercept
acut
respiratori
ill
occur
vaccin
caus
influenza
emphas
import
influenza
vaccin
